Maximizing Market Access for Cell and Gene Therapies in an Era of Uncertainty
Cell and gene therapies offer the potential for long-lasting and potentially curative outcomes for patients with serious and often rare diseases. With the Trump administration’s evolving healthcare policies in relation to cell and gene therapies creating ambiguity around regulatory and reimbursement frameworks, manufacturers must adopt a more proactive posture toward market access strategy to ensure optimal access and product adoption. This white paper outlines six key strategies that will not only improve the odds of reimbursement and adoption but also help ensure that patients who need these life-changing and often curative therapies receive them. (September 2025)
Download the White Paper
"*" indicates required fields